MetaCap

Cytokinetics (CYTK) vs Kiniksa Pharmaceuticals International (KNSA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Kiniksa Pharmaceuticals International (KNSA) has outperformed Cytokinetics (CYTK) over the past year, gaining 125.8% versus a loss of 22.4%. Over five years, KNSA leads with a +706.0% price change compared with +30.1% for CYTK. Kiniksa Pharmaceuticals International is the larger company by market cap ($7.38 billion vs $7.07 billion), about 1.0 times the size, while Cytokinetics is growing revenue faster (+376.6% vs +60.1%).

Kiniksa Pharmaceuticals International converts more of its revenue into profit, with a net margin of 8.7% versus -891.6%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CYTK-22.40%KNSA+125.82%
+146%+58%-30%
Nov 21, 20251 yearNov 20, 2026
CYTK+24.28%KNSA+669.63%
+726%+328%-71%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CYTK versus KNSA key metrics
MetricCYTKKNSA
Share price$50.78$93.90
Market cap$7.07B$7.38B
1-day change-1.32%+0.38%
YTD return-20.08%+127.62%
1-year return-22.40%+125.82%
5-year return+30.11%+705.97%
P/E ratio (TTM)—71.13
Forward P/E—45.91
EPS (TTM)$-6.02$1.32
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$88.04M$677.56M
Revenue growth (YoY)+376.56%+60.09%
Net income (latest FY)$-784.96M$59.01M
Gross margin—88.54%
Operating margin-695.44%11.40%
Net margin-891.60%8.71%
52-week high$88.31$99.31
52-week low$50.32$37.02
Distance from 52-week high-42.50%-5.45%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+115.48%+18.82%
Average volume2.02M664.53K
Shares outstanding139.30M48.84M
Employees673366
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • KNSA has outperformed CYTK by 148.2 percentage points over the past year.
  • Kiniksa Pharmaceuticals International is more profitable, keeping 8.7 cents of every revenue dollar as net income versus -891.6 cents for Cytokinetics.
  • Cytokinetics grew revenue faster in its latest fiscal year (+376.56% vs +60.09%).

About Cytokinetics

CYTK stock →

Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM.

Health Care · Biotechnology: Pharmaceutical Preparations · 673 employees

About Kiniksa Pharmaceuticals International

KNSA stock →

Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis.

Health Care · Biotechnology: Pharmaceutical Preparations · 366 employees

CYTK vs KNSA FAQ

Which is bigger, Cytokinetics or Kiniksa Pharmaceuticals International?

Kiniksa Pharmaceuticals International (KNSA) is larger, with a market capitalization of $7.38B compared with $7.07B for Cytokinetics (CYTK).

Which stock has performed better over the past year, CYTK or KNSA?

KNSA returned +125.82% over the past 12 months, compared with -22.40% for CYTK (price return, excluding dividends). Past performance does not predict future results.

Are Cytokinetics and Kiniksa Pharmaceuticals International in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons